Lesley Portnoy and Aclaris Therapeutics

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc. | Globe Newswire | 9/25/2019

Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS ) investors who purchased securities between May 8, 2018 and June 20, 2019 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc. | Benzinga | 9/25/2019

Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS ) investors who purchased securities between May 8, 2018 and June 20, 2019 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc. | Financial Buzz | 9/25/2019

Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS ) investors who purchased securities between May 8, 2018 and June 20, 2019 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc. | Business Wire | 8/6/2019

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc. August 05, 2019 07:15 PM Eastern Daylight Time LOS ANGELES–( BUSINESS WIRE )– Glancy Prongay & Murray LLP (“GPM”) reminds … rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to , or visit our website at www.glancylaw.com . On June 20, 2019, the U.S …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc. – Company Announcement - FT.com | Financial Times | 8/6/2019

Aclaris Therapeutics , Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS ) investors who purchased securities between May 8, 2018 and June 20, 2019 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy

Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) – Company Announcement - FT.com | Financial Times | 7/31/2019

… a class action lawsuit in the United States District Court for the Southern District of New York , captioned Rosi v. Aclaris Therapeutics , Inc. et al. , (Case No. 1:19-cv-07118), on behalf of persons and … rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire , of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders …

Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) | Business Wire | 7/30/2019

… a class action lawsuit in the United States District Court for the Southern District of New York, captioned Rosi v. Aclaris Therapeutics, Inc. et al. , (Case No. 1:19-cv-07118), on behalf of persons and … rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders …

Glancy Prongay & Murray LLP Continues Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) | Globe Newswire | 7/25/2019

Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS ) investors concerning the Company and its officers’ possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150 …

Glancy Prongay & Murray LLP Continues Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) | Business Wire | 6/27/2019

Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS ) investors concerning the Company and its officers’ possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150 …

Glancy Prongay & Murray LLP Announces Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) | Business Wire | 6/25/2019

Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS ) investors concerning the Company and its officers’ possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150 …